Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May:189:xxiv-xxvii.
doi: 10.1016/j.ajo.2018.02.016. Epub 2018 Mar 1.

What We Have Learned From the Ocular Hypertension Treatment Study

Mae O Gordon  1 , Michael A Kass  2
Affiliations
Review

What We Have Learned From the Ocular Hypertension Treatment Study

Mae O Gordon et al. Am J Ophthalmol. 2018 May.

Abstract

Purpose: To identify results from the Ocular Hypertension Study that can aid patients and clinicians to make evidence-based decisions about the management of ocular hypertension.

Design: Perspective.

Results: At 60 months, the cumulative frequency of developing primary open-angle glaucoma (POAG) was 4.4% in the medication group and 9.5% in the observation group (hazard ratio for medication, 0.40; 95% confidence interval [CI], 0.27-0.59; P < .0001). At 13 years the cumulative proportion of participants who developed POAG was 0.22 (95% CI 0.19-0.25) in the original observation group and 0.16 (95% CI 0.13-0.19) in the original medication group (complementary log-log x2P = .009). A 5-factor model (older age, higher IOP, thinner central corneal thickness, larger cup-to-disc ratio, and higher visual field pattern standard deviation) separated participants at high and low risk of developing POAG.

Conclusions: Clinicians and patients can make evidence-based decisions about the management of ocular hypertension using the risk model and considering patient age, medical status, life expectancy, and personal preference.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative probability of developing primary open-angle glaucoma (POAG) from February 1994 to March 2009 by randomization group. The time between the two vertical lines indicate the initiation of medication in the original observation group.
See this image and copyright information in PMC

Comment in

  • What We Have Learned From the Ocular Hypertension Treatment Study.
    Călugăru D, Călugăru M. Călugăru D, et al. Am J Ophthalmol. 2018 Aug;192:248-249. doi: 10.1016/j.ajo.2018.03.045. Am J Ophthalmol. 2018. PMID: 29759296 No abstract available.
  • Reply.
    Gordon MO, Kass MA. Gordon MO, et al. Am J Ophthalmol. 2018 Aug;192:249. doi: 10.1016/j.ajo.2018.04.019. Epub 2018 May 31. Am J Ophthalmol. 2018. PMID: 29861092 No abstract available.

References

    1. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975. Surv Ophthalmol. 1980;24(Suppl):335–610. - PubMed
    1. Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study G The Ocular Hypertension Treatment Study: Design and Baseline Description of the Participants. Archives of Opthalmology. 1999;117:573–583. - PubMed
    1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study – A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology. 2002;120(6):701–13. - PubMed
    1. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714–20. discussion 829–30. - PubMed
    1. Miglior S, Zeyen T, Pfeiffer N, et al. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005;112(3):366–75. - PubMed

Publication types

MeSH terms

Substances